Market Intelligence, Clinical Progress, and High-Purity Reagents for Hepatocellular Carcinoma and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GPC3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPC3 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed, native glycosylation and heparan sulfate modifications preserved. |
View GPC3 Products |
| Gene Delivery | GPC3 Promise-ORF / Lentivirus Full-length GPI-anchored ORF for stable cell lines. Preserves native membrane topology. |
View GPC3 Products |
| Benchmark Ab | Anti-GPC3 (Codrituzumab/GC33 Sequence) Recombinant positive control for binding comparison and assay development. |
View GPC3 Products |
| Validator | GPC3 siRNA Set For knockdown verification and specificity controls. |
View GPC3 Products |
| Related Target A | CD3 Synergistic pathway for T-cell engagers (bispecifics). |
View CD3 Products |
| Related Target B | GPC1 Closest family member; critical for selectivity counter-screening. |
View GPC1 Products |
| Related Target C | GPC5 Paralog family member; assess off-target toxicity risk. |
View GPC5 Products |
| Related Target D | FGFR4 Co-receptor in the GPC3/FGF19 oncogenic signaling axis; essential for combination studies. |
View FGFR4 Products |
| Related Target E | FGF19 Synergistic ligand whose signaling is potentiated by GPC3 in hepatocellular carcinoma. |
View FGF19 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity; sequence verified. |
| Glypican family selectivity (GPC1/GPC5 cross-reactivity) | Homolog panel proteins (GPC1-6) strictly verified by mass spec for strict counter-screening. |
| Internalization efficiency for ADC development | High-purity ECD-Fc (>95%) with native conformation; suitable for pH-dependent binding and FACS-based internalization assays. |
| Native GPI-anchored membrane presentation | Lentivirus-based stable cell lines preserve native GPI-anchored topology for flow cytometry and internalization studies. |
| Non-human primate toxicology bridging | Cynomolgus GPC3 protein available with >95% homology to human target; supports toxicology bridging. |
| Lack of Controls | Clinical Benchmark Antibodies (Codrituzumab/GC33 biosimilar sequence) included as recombinant positive controls. |
| False Positives | Validated siRNA included for specificity checks and target engagement confirmation. |
Live GPC3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GPC3 therapeutics is intensifying, with major players shifting focus from first-generation monoclonal antibodies (e.g., Codrituzumab/GC33) to next-generation modalities including ADCs, bispecific T-cell engagers, and CAR-T cell therapies. First-generation agents established proof-of-concept in hepatocellular carcinoma (HCC), but the field is rapidly evolving toward T-cell redirecting bispecifics (e.g., ERY974, ZGGS18) and autologous CAR-T approaches (e.g., CT011) to overcome the immunosuppressive tumor microenvironment of solid tumors.
As first-generation therapies reach the clinic, the next wave of R&D is targeting combination strategies with immune checkpoint inhibitors, subcutaneous delivery formats for bispecifics, and refined patient selection based on GPC3 expression heterogeneity. ADCs require rigorous internalization and lysosomal trafficking validation, while CAR-T and bispecifics demand robust cell-based cytotoxicity and cytokine release assays. Emerging trends include dual-targeting approaches (e.g., GPC3/PD-L1), radio-immunotherapy, and armed cell therapies with bystander effects. Collectively, these developments necessitate assay reagents that accurately replicate native GPI-anchored topology and provide species-cross-reactive benchmarks for translational toxicology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Roche/Chugai (Codrituzumab/GC33) | Hepatocellular Carcinoma (HCC) | Affinity & selectivity assay (high-purity ECD-Fc; paralog counter-screen) |
| Bispecific T-cell Engager | Roche/Chugai (ERY974), Zai Lab (ZGGS18) | Solid Tumors (HCC, Ovarian Cancer) | Heterodimer validation & T-cell activation (cross-reactive Abs; stable GPC3+ cell line) |
| CAR-T Cell Therapy | CARsgen (CT011), Novartis, Academic Centers | Refractory HCC, Solid Tumors (Lung) | Cell-based cytotoxicity & cytokine release (lentivirus-stable GPC3+ target cells) |
| ADC | Roche/Chugai, BeiGene, Innovent | HCC, Solid Tumors | Internalization & lysosomal trafficking assay (high-purity ECD-Fc with native heparan sulfate) |
| Radio-immunotherapy | Northwest Biotherapeutics | Recurrent HCC | Binding affinity quantification (SPR-ready proteins) |